NEW YORK (GenomeWeb) – Lineagen said today that it is partnering with telemedicine company PWNHealth to expand access to its clinical genetic tests through a consumer-initiated model.
Lineagen provides testing services to individuals with developmental delay and autism spectrum disorder, including a chromosomal microarray assay called FirstStep Plus and a whole-exome sequencing test called NextStep Plus. These tests require an order from a licensed healthcare provider.
Through its partnership with PWNHealth, Lineagen will develop a digital platform that streamlines the ordering process for its tests while maintaining the requisite oversight and guidance of licensed clinical providers and genetic counselors, Lineagen said.
"Time matters for these kids and their families," Lineagen CEO Michael Paul said in a statement. "Lineagen is committed to helping reduce the diagnostic and clinical odyssey experienced by many individuals and families across the autism and neurodevelopmental disorder spectrum. Our partnership with PWNHealth represents an important step towards fulfilling our commitment to enhance and accelerate diagnostic testing by leveraging innovations in telehealth."
Financial and other terms of the agreement were not disclosed.